07:52 EDT Lexeo Therapeutics (LXEO) up 31% at $8.50 after update on LX2006 accelerated approval
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics Advances FDA Discussions for LX2006
- Lexeo Therapeutics reports on LX2006 approval pathway
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Lexeo Therapeutics price target lowered to $15 from $20 at Chardan
- Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Strategic Positioning in Cardiac Treatments